• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血友病治疗的进展:在 2010 年世界血友病大会上的两个专题讨论会的报告。

Advances in hemophilia care: report of two symposia at the Hemophilia 2010 World Congress.

机构信息

Nottingham Haemophilia Comprehensive Care Centre, University Hospital, Queen's Medical Centre, Derby Road, Nottingham, NG7 2UH, UK.

出版信息

Adv Ther. 2012 Apr;29 Suppl 1:1-16. doi: 10.1007/s12325-012-0010-3. Epub 2012 Mar 16.

DOI:10.1007/s12325-012-0010-3
PMID:22467446
Abstract

The World Federation of Hemophilia (WFH) 2010 World Congress held in Buenos Aires, Argentina, in July 2010, attracted more than 4,300 participants from 106 countries. This report summarizes two symposia held during the congress. The first, titled "Emerging Co-Morbidities in the Aging Hemophilia Population: Healthcare Challenges and Treatment Opportunities," chaired by Gerry Dolan, MD, and Jussara Almeida Cruz, MD, examined the co-morbidities experienced by the aging hemophilic patient population, such as cardiovascular disease, cancer, arthritis, osteoporosis, hypertension, and obesity. In addition, Bayer's products in preclinical and clinical development were reviewed, including a novel factor VIIa variant and a long-acting factor VIII molecule, i.e., one that has undergone site-specific PEGylation (attachment of polyethylene glycol [PEG] polymer chains to another molecule). The other symposium, titled "Practical Steps to Making Better Care for Hemophilia Patients a Reality," chaired by Carmen Altisent, MD, and Cesar Guerrero, RN, reviewed the steps that hemophilia caregivers can take to improve the care of their patients. Issues such as the treatment of hemarthroses, the role of the research nurse, and the management of pediatric patients transitioning to adulthood were discussed.

摘要

世界血友病联盟(WFH)2010 年世界大会于 2010 年 7 月在阿根廷布宜诺斯艾利斯举行,吸引了来自 106 个国家的 4300 多名参与者。本报告总结了大会期间举行的两个专题讨论会。第一个专题讨论会的标题是“老龄化血友病人群中的新兴合并症:医疗保健挑战和治疗机会”,由医学博士杰里·多兰(Gerry Dolan)和医学博士儒萨娜·阿尔梅达·克鲁兹(Jussara Almeida Cruz)共同主持,探讨了老龄化血友病患者人群中所经历的合并症,如心血管疾病、癌症、关节炎、骨质疏松症、高血压和肥胖症。此外,还审查了拜耳公司处于临床前和临床开发阶段的产品,包括一种新型凝血因子 VIIa 变体和一种长效凝血因子 VIII 分子,即经过特异性聚乙二醇化(将聚乙二醇[PEG]聚合物链连接到另一种分子上)的凝血因子 VIII 分子。另一个专题讨论会的标题是“采取切实步骤,使血友病患者获得更好的护理”,由医学博士卡门·阿尔腾西斯(Carmen Altisent)和注册护士塞萨尔·格雷罗(Cesar Guerrero)共同主持,探讨了血友病护理人员可以采取哪些步骤来改善对患者的护理。讨论了诸如关节积血的治疗、研究护士的作用以及儿科患者向成年期过渡的管理等问题。

相似文献

1
Advances in hemophilia care: report of two symposia at the Hemophilia 2010 World Congress.血友病治疗的进展:在 2010 年世界血友病大会上的两个专题讨论会的报告。
Adv Ther. 2012 Apr;29 Suppl 1:1-16. doi: 10.1007/s12325-012-0010-3. Epub 2012 Mar 16.
2
The hope and reality of long-acting hemophilia products.长效血友病产品的希望与现实。
Am J Hematol. 2012 May;87 Suppl 1:S33-9. doi: 10.1002/ajh.23146. Epub 2012 Mar 3.
3
Demographics of hemophilia in developing countries.发展中国家血友病的人口统计学情况。
Semin Thromb Hemost. 2005 Nov;31(5):489-94. doi: 10.1055/s-2005-922218.
4
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.血友病和血管性血友病:2. 管理。加拿大血友病诊所主任协会
CMAJ. 1995 Jul 15;153(2):147-57.
5
Pioneering designs for recombinant coagulation factors.重组凝血因子的开拓性设计。
Thromb Res. 2011;128 Suppl 1:S9-12. doi: 10.1016/S0049-3848(12)70003-8.
6
Treatment of hemophilia.血友病的治疗。
Ric Clin Lab. 1985 Oct-Dec;15(4):289-303.
7
Hemophilia in Iran.伊朗的血友病
Hematology. 2016 Jun;21(5):300-10. doi: 10.1080/10245332.2015.1125080. Epub 2016 Feb 24.
8
FEIBA versus NovoSeven in hemophilia patients with inhibitors.FEIBA 与 NovoSeven 在有抑制剂的血友病患者中的比较。
Semin Thromb Hemost. 2013 Oct;39(7):772-8. doi: 10.1055/s-0033-1354425. Epub 2013 Sep 8.
9
Management of joint bleeding in hemophilia.血友病关节出血的管理。
Expert Rev Hematol. 2012 Aug;5(4):459-68. doi: 10.1586/ehm.12.27.
10
Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia.血友病青少年(18-30 岁)的治疗效果、生活质量及对其的影响。
Am J Hematol. 2015 Dec;90 Suppl 2:S3-10. doi: 10.1002/ajh.24220.